Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2521–2544 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: West Syndrome
Interventions: adrenocorticotropin hormone; Drug
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 2 Months to 12 Months
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Smoldering Multiple Myeloma
Interventions: Carfilzomib, Lenalidomide, Daratumumab, Dexamethasone; Drug
Lead sponsor: International Myeloma Foundation; Other
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2031
U.S. locations: 10
States / cities: Tampa, Florida • Chicago, Illinois • Indianapolis, Indiana + 7 more

Conditions: Prostate Cancer
Interventions: Xaluritamig, GnRH Antagonist; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 7
States / cities: San Francisco, California • St Louis, Missouri • Columbus, Ohio + 4 more

Conditions: Sarcoma
Interventions: TIL, Interleukin-2, Fludarabine, Cyclophosphamide; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years to 39 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Coronary Artery Disease, High Risk Percutaneous Coronary Intervention, Interventional Cardiology, Mechanical Circulatory Support
Interventions: The Supira System, Impella; Device
Lead sponsor: Supira Medical; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 26
States / cities: Loma Linda, California • Sacramento, California • Thousand Oaks, California + 21 more

Conditions: Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Adenocarcinoma, Advanced Primary Peritoneal Carcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing, Elimusertib, Gemcitabine; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 3
States / cities: Bethesda, Maryland • Boston, Massachusetts

Conditions: HIV Prevention, HIV Infections
Interventions: tenofovir + emtricitabine, lopinavir/ritonavir; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, Linagliptin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 6,991 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 197
States / cities: Huntsville, Alabama • Scottsboro, Alabama • Tuscumbia, Alabama + 150 more

Conditions: PreTerm Birth, PreTerm Neonate
Interventions: Delayed Cord Clamping, Immediate Cord Clamping; Procedure
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Sarcoma
Interventions: filgrastim, cisplatin, doxorubicin hydrochloride, ifosfamide, melphalan, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 10 Years to 55 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2014
U.S. locations: 1
States / cities: Duarte, California

Conditions: Head and Neck Cancer
Interventions: Xevinapan, Cisplatin, External beam; Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Uveal Melanoma
Interventions: Crizotinib; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 4
States / cities: Miami Beach, Florida • New York, New York • Columbus, Ohio

Conditions: Surgical Site Infection
Interventions: povidone-iodine topical ointment; Drug
Lead sponsor: Loreen Herwaldt; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 6
States / cities: Atlanta, Georgia • Indianapolis, Indiana • Iowa City, Iowa + 3 more

Conditions: Severe Respiratory Disease
Interventions: High Risk Respiratory Disease; Behavioral
Lead sponsor: MedImmune LLC; Industry
Eligibility: 1 Day to 24 Months
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 16
States / cities: Long Beach, California • Denver, Colorado • Chicago, Illinois + 13 more

Conditions: Preterm Premature Rupture of the Membranes, Pregnancy Complications, Pregnancy, High Risk
Interventions: Ambulation Group, Routine Care; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 12 Years to 55 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Endometrial Endometrioid Adenocarcinoma, Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Interventions: Biospecimen Collection, Brachytherapy, Computed Tomography, External Beam Radiation Therapy, Magnetic Resonance Imaging, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration, X-Ray Imaging; Procedure · Radiation · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 275
States / cities: Birmingham, Alabama • Clovis, California • Concord, California + 195 more

Conditions: Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Interventions: Oral Azacitidine, Rituximab, cyclophosphamide, Vincristine, Prednisone; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 7
States / cities: Tampa, Florida • Chicago, Illinois • Boston, Massachusetts + 3 more

Conditions: Leukemia
Interventions: Clofarabine, Idarubicin, Cytarabine, Fludarabine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Neuroblastoma
Interventions: cyclophosphamide, topotecan, hu14.18K322A, peripheral blood stem cell harvest, surgical resection, cisplatin, etoposide, doxorubicin, vincristine, busulfan, melphalan, peripheral blood stem cell transplantation, natural killer cell infusion, radiation therapy, GM-CSF, G-CSF, mesna, levetiracetam, interleukin-2, Isotretinoin, CliniMACS; Drug · Biological · Procedure + 2 more
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 18 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v7, Stage IIB Colon Cancer AJCC v7, Stage IIC Colon Cancer AJCC v7
Interventions: Bevacizumab, Fluorouracil, Leucovorin, Oxaliplatin; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 2,431 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2026
U.S. locations: 910
States / cities: Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 578 more

Conditions: Brain and Central Nervous System Tumors
Interventions: filgrastim, carboplatin, thiotepa, autologous bone marrow transplantation, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 6 Years to 59 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1994
U.S. locations: 1
States / cities: New York, New York

Conditions: Osteosarcoma, Medulloblastoma, Sarcoma, Ewing's, Neuroblastoma (Measurable Disease), Neuroblastoma (Metaiodobenzylguanidine, Positive Evaluable), Rhabdomyosarcoma, Ependymoma, Non-brainstem High-grade Glioma
Interventions: pemetrexed; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: Up to 22 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Arcadia, California

Conditions: Autism, Autism Spectrum Disorder High-Functioning, Developmental Disability, Child Development, Behavior, Child, Behavior, Social
Interventions: PRT for Adolescents; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 11 Years to 14 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Breast Cancer
Interventions: Doxorubicin, Cyclophosphamide, Docetaxel, Paclitaxel; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 4,242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2025
U.S. locations: 914
States / cities: Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 612 more

Search by objective public record fields.

Prevention of West Syndrome With Low-dose Adrenocorticotropin Hormone (ACTH)

Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant

Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma

Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)

Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors

Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

Trial of Immediate vs. Delayed Cord Clamping in the Preterm Neonate

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Sarcoma

A Study of Xevinapant With Cisplatin and Radiation Therapy After Surgery in People With Head and Neck Cancer

Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy

PVI to Prevent S. Aureus SSI After Fixation of HELEF (POTENT Study)

Study to Evaluate the Human Infection of the Lower Respiratory Tract in Children at High Risk

Ambulation for Latency During Expectant Management of PPROM

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma

Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome

Therapy for Children With Advanced Stage Neuroblastoma

Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Glioblastoma Multiforme or Brain Stem Tumors

A Study of Pemetrexed in Children With Recurrent Cancer

PRT for Adolescents With High Functioning Autism

Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer